PharmaLive: Agency News

ST. LOUIS--(BUSINESS WIRE)--Apr 6, 2005 - QualiLife Pharmaceuticals, Inc., a science-driven company focused on developing and commercializing clinically proven consumer products in women's health, has selected Kupper Parker Communications, Inc. (OTCBB:KPCG) as its agency of record to provide public relations, advertising and representation services for the company's $20 million marketing campaign. Through an integrated marketing program, KPC will increase awareness, distribution and sales of Zestra(TM), QualiLife Pharmaceuticals' non-prescription "Feminine Arousal Fluid" (US Patent 6,737,084). Zestra(TM) is the only product of its kind whose clinical study results are published in peer-reviewed medical journals.

"Zestra(TM) represents a scientific breakthrough for the millions of women experiencing sexual arousal problems(1), and we recognize the tremendous opportunity and responsibility to educate women and their healthcare providers about the issue and the availability of our clinically proven product," said Pharmacologist Martin Crosby, President & Chief Scientific Officer of QualiLife Pharmaceuticals, Inc. "We selected KPC to take our product awareness to the next level based on the combination of their successful track record in launching consumer products, their healthcare expertise and their solid commitment for getting results."

"We are very proud to work with QualiLife Pharmaceuticals because of their established commitment to clinical and scientific integrity, product quality and performance," said Bruce Kupper, president and chief executive officer of KPC. "The market opportunity for a clinically-proven, non-prescription solution is immense and we are pleased to be QualiLife's partner in maximizing the commercial opportunity for Zestra(TM) Feminine Arousal Fluid."

Since the introduction of Viagra(R) for men in May 1998, pharmaceutical companies have been racing to develop a solution for women by trying to adapt existing "male" prescription Erectile Dysfunction (ED) drugs for potential use in female sexual complaints but those drugs have met with little to no success in women. In fact, there are still no FDA approved prescription drugs for the "treatment" of any form of female sexual dysfunction (FSD).

Crosby continued, "Non-prescription Zestra(TM) is the proven, all-natural solution for most women who experience sexual problems such as difficulty with arousal, sensation, pleasure, orgasm, overall satisfaction and libido. Zestra(TM) is topically applied, hormone-free and is not a drug. No other product is proven to be more effective at increasing female sexual pleasure."

In April 1996, QualiLife Pharmaceuticals focused its research and development in women's sexual health with the goal of developing and commercializing science-based proprietary natural product formulations to successfully address large unmet needs in women's health. In addition to QualiLife's flagship product Zestra(TM), the company has additional consumer products in late-stage development that address other unmet needs in women's health.

For more information about KPC visit www.kupperparker.com. For more information about QualiLife Pharmaceuticals, Inc. and Zestra(TM) visit www.zestraforwomen.com.

Headquartered in St. Louis, KPC is among the nation's leading independent marketing communications firms, providing a full range of services domestically and internationally through its offices and affiliates in the United States and Europe. KPC's U.S. markets include: Boston; Kansas City, Mo.; Louisville, Ky.; Memphis, Tenn.; Melville, NY; Oklahoma City, Ok.; and St. Louis. KPC extends its services in Europe through an ownership interest in Communications in Business, headquartered in London with offices in Brussels, Dusseldorf, Milan, Paris and Madrid. KPC ranks in the top 20 independent agency brands in the U.S. according to 2004 editions of AdWeek, AdAge and PRWeek.

Safe Harbor

Statements included in this news release may contain forward-looking statements, including but not limited to statements of the Company's plans, objectives, expectations or intentions, that involve risk and uncertainties. The Company's actual results may differ significantly from those projected or suggested in any forward-looking statement due to a variety of factors, which are discussed in detail in the Company's filings with the Securities and Exchange Commission.

(1) Some form of female sexual dysfunction is prevalent in approximately 43 percent of the female population according to "Sexual Dysfunction in the United States: Prevalence and Predictors," Journal of the American Medical Association, February 10, 1999.

CORPORATE CONTACT:
Martin G. Crosby
Chairman & Chief Science Officer
Zestra Laboratories, Inc.
4055 Faber Place Drive, Suite 300
Charleston, SC 29405
843.402.0901 (phone)
843.402.0919 (fax)
www.zestraforwomen.com

Download the PDF version.